Recent Progress on Immunotherapy for Breast Cancer: Tumor Microenvironment, Nanotechnology and More
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Recent Progress on Immunotherapy for Breast Cancer: Tumor Microenvironment, Nanotechnology and More
Authors
Keywords
-
Journal
Frontiers in Bioengineering and Biotechnology
Volume 9, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-06-02
DOI
10.3389/fbioe.2021.680315
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Triple-Negative Breast Cancer: Intact Mismatch Repair and Partial Co-Expression of PD-L1 and LAG-3
- (2021) Shafei Wu et al. Frontiers in Immunology
- Mismatch Repair Deficiency and Microsatellite Instability in Triple-Negative Breast Cancer: A Retrospective Study of 440 Patients
- (2021) Xin-yu Ren et al. Frontiers in Oncology
- JSCO—ESMO—ASCO—JSMO—TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions
- (2020) T. Yoshino et al. ANNALS OF ONCOLOGY
- Engineering Polymeric Prodrug Nanoplatform for Vaccination Immunotherapy of Cancer
- (2020) Lei Zhou et al. NANO LETTERS
- Oncolytic vesicular stomatitis virus–based cellular vaccine improves triple-negative breast cancer outcome by enhancing natural killer and CD8+T-cell functionality
- (2020) Seyedeh-Raheleh Niavarani et al. Journal for ImmunoTherapy of Cancer
- Multifunctional Smart Yolk-Shell Nanostructure with Mesoporous MnO2 Shell for Enhanced Cancer Therapy
- (2020) Hongjun Zhuang et al. ACS Applied Materials & Interfaces
- HER2-LAMP vaccines effectively traffic to endolysosomal compartments and generate enhanced polyfunctional T cell responses that induce complete tumor regression
- (2020) Alan Chen Chen et al. Journal for ImmunoTherapy of Cancer
- Nanoparticle-enhanced chemo-immunotherapy to trigger robust antitumor immunity
- (2020) Jingjing Liang et al. Science Advances
- Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
- (2020) Javier Cortes et al. LANCET
- A brief report of toxicity end points of HER2 vaccines for the treatment of patients with HER2+ breast cancer
- (2019) Ricardo Costa et al. Drug Design Development and Therapy
- Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial
- (2019) Sherene Loi et al. LANCET ONCOLOGY
- A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple negative breast cancer – clinical results and biomarker analysis of GeparNuevo study
- (2019) S Loibl et al. ANNALS OF ONCOLOGY
- Efficacy and Safety Analysis of Nelipepimut-S Vaccine to Prevent Breast Cancer Recurrence: A Randomized, Multicenter, Phase III Clinical Trial
- (2019) Elizabeth A. Mittendorf et al. CLINICAL CANCER RESEARCH
- Phospho‑STAT1 expression as a potential biomarker for anti‑PD‑1/anti‑PD‑L1 immunotherapy for breast cancer
- (2019) Yuko Nakayama et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial
- (2019) Leonie Voorwerk et al. NATURE MEDICINE
- Ligand‐Installed Nanocarriers toward Precision Therapy
- (2019) Peng Mi et al. ADVANCED MATERIALS
- Phase I study of local radiation and tremelimumab in patients with inoperable locally recurrent or metastatic breast cancer
- (2019) Di (Maria) Jiang et al. Oncotarget
- CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth
- (2019) Ru Zhou et al. Frontiers in Immunology
- Open-Label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer
- (2019) Shaveta Vinayak et al. JAMA Oncology
- Tumor-infiltrating lymphocytes and CD8+ T cells predict survival of triple-negative breast cancer
- (2019) H. Vihervuori et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- In vivo molecular imaging for immunotherapy using ultra-bright near-infrared-IIb rare-earth nanoparticles
- (2019) Yeteng Zhong et al. NATURE BIOTECHNOLOGY
- A Phase Ib Trial of Durvalumab in Combination with Trastuzumab in HER2‐Positive Metastatic Breast Cancer (CCTG IND.229)
- (2019) Stephen Chia et al. ONCOLOGIST
- PD-L1 expression is a predictive biomarker for CIK cell-based immunotherapy in postoperative patients with breast cancer
- (2019) Zi-Qi Zhou et al. Journal for ImmunoTherapy of Cancer
- JQ1-Loaded Polydopamine Nanoplatform Inhibits c-MYC/Programmed Cell Death Ligand 1 to Enhance Photothermal Therapy for Triple-Negative Breast Cancer
- (2019) Ying Tian et al. ACS Applied Materials & Interfaces
- Tumor microenvironment and breast cancer survival: combined effects of breast fat, M2 macrophages and hyaluronan create a dismal prognosis
- (2019) Satu Tiainen et al. BREAST CANCER RESEARCH AND TREATMENT
- A phase 2 clinical trial assessing the efficacy and safety of pembrolizumab and radiotherapy in patients with metastatic triple‐negative breast cancer
- (2019) Alice Y. Ho et al. CANCER
- Rapid generation of sustainable HER2-specific T cell immunity in HER2 breast cancer patients using a degenerate HLA class II epitope vaccine
- (2019) Keith L Knutson et al. CLINICAL CANCER RESEARCH
- Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Peter Schmid et al. LANCET ONCOLOGY
- The Immune Microenvironment in Breast Carcinoma: Predictive and Prognostic Role in the Neoadjuvant Setting
- (2019) Nahla M. Badr et al. PATHOBIOLOGY
- EGFR-specific CAR-T cells trigger cell lysis in EGFR-positive TNBC
- (2019) Yan Liu et al. Aging-US
- Application of E75 peptide vaccine in breast cancer patients: A systematic review and meta-analysis
- (2018) Reyhane Chamani et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Immunotherapeutic interventions of Triple Negative Breast Cancer
- (2018) Zehuan Li et al. Journal of Translational Medicine
- A novel chimeric antigen receptor containing a JAK–STAT signaling domain mediates superior antitumor effects
- (2018) Yuki Kagoya et al. NATURE MEDICINE
- Clinical implication of tumor mutational burden in patients with HER2-positive refractory metastatic breast cancer
- (2018) Song Ee Park et al. OncoImmunology
- The viral approach to breast cancer immunotherapy
- (2018) Atefeh Arab et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Tumor mutational burden is a determinant of immune-mediated survival in breast cancer
- (2018) Alexandra Thomas et al. OncoImmunology
- Breast Cancer Chemo-immunotherapy through Liposomal Delivery of an Immunogenic Cell Death Stimulus Plus Interference in the IDO-1 Pathway
- (2018) Jianqin Lu et al. ACS Nano
- Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study
- (2018) S Adams et al. ANNALS OF ONCOLOGY
- CRISPR/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions
- (2018) Wanghong Hu et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
- (2018) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up
- (2018) Sylvia Adams et al. JAMA Oncology
- Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
- (2017) Aaron M. Goodman et al. MOLECULAR CANCER THERAPEUTICS
- First FDA Approval Agnostic of Cancer Site — When a Biomarker Defines the Indication
- (2017) Steven Lemery et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 blockade reverses adaptive immune resistance induced by high-dose hypofractionated but not low-dose daily fractionated radiation
- (2017) Megan Morisada et al. OncoImmunology
- Clinical Validity and Utility of Tumor-Infiltrating Lymphocytes in Routine Clinical Practice for Breast Cancer Patients: Current and Future Directions
- (2017) Lironne Wein et al. Frontiers in Oncology
- A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling
- (2016) H. L. McArthur et al. CLINICAL CANCER RESEARCH
- Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy
- (2016) Christina Pfirschke et al. IMMUNITY
- Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy
- (2016) Lewis Zhichang Shi et al. Nature Communications
- Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor- B to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer
- (2015) J. Peng et al. CANCER RESEARCH
- Cancer immunotherapy using novel tumor-associated antigenic peptides identified by genome-wide cDNA microarray analyses
- (2015) Yasuharu Nishimura et al. CANCER SCIENCE
- Prognostic and predictive value of tumor-infiltrating lymphocytes in breast cancer: a systematic review and meta-analysis
- (2015) X. Yu et al. Clinical & Translational Oncology
- PD-L1 Expression in Triple-Negative Breast Cancer
- (2014) E. A. Mittendorf et al. Cancer Immunology Research
- Nanooncology: The future of cancer diagnosis and therapy
- (2013) Avnesh S. Thakor et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance
- (2013) Laurence Zitvogel et al. IMMUNITY
- Image-guided Thermal Ablation of Tumors Increases the Plasma Level of Interleukin-6 and Interleukin-10
- (2013) Joseph P. Erinjeri et al. JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY
- Changes in interleukin-1β and 6 after hepatic microwave tissue ablation compared with radiofrequency, cryotherapy and surgical resections
- (2010) Fateh Ahmad et al. AMERICAN JOURNAL OF SURGERY
- First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity
- (2010) Chrystelle Brignone et al. Journal of Translational Medicine
- Systemic inflammatory response and downmodulation of peripheral CD25+Foxp3+ T-regulatory cells in patients undergoing radiofrequency thermal ablation for lung cancer
- (2009) Anna Maria Fietta et al. HUMAN IMMUNOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search